CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to improve treatment for hyperinsulinaemic hypoglycaemia by developing a combined imaging and therapy platform. It focuses on precise diagnosis and targeted destruction of malfunctioning pancreatic beta cells to enhance patient outcomes, particularly in infants.
Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans.
Lethal HH and brain damage is a problem especially in infants with congenital HH.
Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, HEERENVEEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAIR MEDISCH CENTRUM GRONINGEN
Netherlands, Groningen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany, Berlin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
